<?xml version='1.0' encoding='utf-8'?>
<document id="17364639"><sentence text="Dyskinesias associated with atomoxetine in combination with other psychoactive drugs."><entity charOffset="28-39" id="DDI-PubMed.17364639.s1.e0" text="atomoxetine" /></sentence><sentence text="Toxicity experience with atomoxetine, a selective norepinephrine reuptake inhibitor approved for Attention Deficit Hyperactivity Disorder (ADHD), is limited"><entity charOffset="25-36" id="DDI-PubMed.17364639.s2.e0" text="atomoxetine" /><entity charOffset="50-64" id="DDI-PubMed.17364639.s2.e1" text="norepinephrine" /><pair ddi="false" e1="DDI-PubMed.17364639.s2.e0" e2="DDI-PubMed.17364639.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17364639.s2.e0" e2="DDI-PubMed.17364639.s2.e1" /></sentence><sentence text=" We report two cases of neurologic complications requiring hospitalization in patients when atomoxetine was added to other psychoactive drugs"><entity charOffset="92-103" id="DDI-PubMed.17364639.s3.e0" text="atomoxetine" /></sentence><sentence text=" A 9-year-old taking clonidine and dextroamphetamine developed psychosis, abnormal involuntary movements, and insomnia"><entity charOffset="21-30" id="DDI-PubMed.17364639.s4.e0" text="clonidine" /><entity charOffset="35-52" id="DDI-PubMed.17364639.s4.e1" text="dextroamphetamine" /><pair ddi="false" e1="DDI-PubMed.17364639.s4.e0" e2="DDI-PubMed.17364639.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17364639.s4.e0" e2="DDI-PubMed.17364639.s4.e1" /></sentence><sentence text=" An 18-year-old also initiating venlafaxine developed facial tics, tremors, and speech disturbance"><entity charOffset="32-43" id="DDI-PubMed.17364639.s5.e0" text="venlafaxine" /></sentence><sentence text=" Acute symptoms did not respond to diphenhydramine in either case, but resolved after atomoxetine and other medications were discontinued"><entity charOffset="35-50" id="DDI-PubMed.17364639.s6.e0" text="diphenhydramine" /><entity charOffset="86-97" id="DDI-PubMed.17364639.s6.e1" text="atomoxetine" /><pair ddi="false" e1="DDI-PubMed.17364639.s6.e0" e2="DDI-PubMed.17364639.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17364639.s6.e0" e2="DDI-PubMed.17364639.s6.e1" /></sentence><sentence text=" Possible explanations include atypical atomoxetine effect, excess atomoxetine or metabolites due to poor metabolizer status (CYP 2D6 polymorphism/deficiency), a drug-drug interaction leading to elevated drug levels or to excess synaptic norepinephrine or dopamine"><entity charOffset="40-51" id="DDI-PubMed.17364639.s7.e0" text="atomoxetine" /><entity charOffset="67-78" id="DDI-PubMed.17364639.s7.e1" text="atomoxetine" /><entity charOffset="238-252" id="DDI-PubMed.17364639.s7.e2" text="norepinephrine" /><entity charOffset="256-264" id="DDI-PubMed.17364639.s7.e3" text="dopamine" /><pair ddi="false" e1="DDI-PubMed.17364639.s7.e0" e2="DDI-PubMed.17364639.s7.e0" /><pair ddi="false" e1="DDI-PubMed.17364639.s7.e0" e2="DDI-PubMed.17364639.s7.e1" /><pair ddi="false" e1="DDI-PubMed.17364639.s7.e0" e2="DDI-PubMed.17364639.s7.e2" /><pair ddi="false" e1="DDI-PubMed.17364639.s7.e0" e2="DDI-PubMed.17364639.s7.e3" /><pair ddi="false" e1="DDI-PubMed.17364639.s7.e1" e2="DDI-PubMed.17364639.s7.e1" /><pair ddi="false" e1="DDI-PubMed.17364639.s7.e1" e2="DDI-PubMed.17364639.s7.e2" /><pair ddi="false" e1="DDI-PubMed.17364639.s7.e1" e2="DDI-PubMed.17364639.s7.e3" /><pair ddi="false" e1="DDI-PubMed.17364639.s7.e2" e2="DDI-PubMed.17364639.s7.e2" /><pair ddi="false" e1="DDI-PubMed.17364639.s7.e2" e2="DDI-PubMed.17364639.s7.e3" /></sentence><sentence text=" Serotonin syndrome is a possibility in the second case, but not the first"><entity charOffset="1-10" id="DDI-PubMed.17364639.s8.e0" text="Serotonin" /></sentence><sentence text=" Clinicians should be aware of emergent dyskinesias when combining atomoxetine with dopaminergic, noradrenergic, or serotonergic medications"><entity charOffset="67-78" id="DDI-PubMed.17364639.s9.e0" text="atomoxetine" /></sentence><sentence text="" /></document>